145 related articles for article (PubMed ID: 9275094)
1. QSAR models for binding of estrogenic compounds to estrogen receptor alpha and beta subtypes.
Tong W; Perkins R; Xing L; Welsh WJ; Sheehan DM
Endocrinology; 1997 Sep; 138(9):4022-5. PubMed ID: 9275094
[TBL] [Abstract][Full Text] [Related]
2. Comparison of estrogen receptor alpha and beta subtypes based on comparative molecular field analysis (CoMFA).
Xing L; Welsh WJ; Tong W; Perkins R; Sheehan DM
SAR QSAR Environ Res; 1999; 10(2-3):215-37. PubMed ID: 10491851
[TBL] [Abstract][Full Text] [Related]
3. CoMFA and docking study of novel estrogen receptor subtype selective ligands.
Wolohan P; Reichert DE
J Comput Aided Mol Des; 2003; 17(5-6):313-28. PubMed ID: 14635724
[TBL] [Abstract][Full Text] [Related]
4. Quantitative structure-activity relationships (QSARs) for estrogen binding to the estrogen receptor: predictions across species.
Tong W; Perkins R; Strelitz R; Collantes ER; Keenan S; Welsh WJ; Branham WS; Sheehan DM
Environ Health Perspect; 1997 Oct; 105(10):1116-24. PubMed ID: 9353176
[TBL] [Abstract][Full Text] [Related]
5. Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17 beta: a 3D QSAR study.
Wiese TE; Polin LA; Palomino E; Brooks SC
J Med Chem; 1997 Oct; 40(22):3659-69. PubMed ID: 9357533
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional quantitative structure-activity relationship study of nonsteroidal estrogen receptor ligands using the comparative molecular field analysis/cross-validated r2-guided region selection approach.
Sadler BR; Cho SJ; Ishaq KS; Chae K; Korach KS
J Med Chem; 1998 Jun; 41(13):2261-7. PubMed ID: 9632359
[TBL] [Abstract][Full Text] [Related]
7. Ligand-based identification of environmental estrogens.
Waller CL; Oprea TI; Chae K; Park HK; Korach KS; Laws SC; Wiese TE; Kelce WR; Gray LE
Chem Res Toxicol; 1996 Dec; 9(8):1240-8. PubMed ID: 8951225
[TBL] [Abstract][Full Text] [Related]
8. QSAR models using a large diverse set of estrogens.
Shi LM; Fang H; Tong W; Wu J; Perkins R; Blair RM; Branham WS; Dial SL; Moland CL; Sheehan DM
J Chem Inf Comput Sci; 2001; 41(1):186-95. PubMed ID: 11206373
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional models of non-steroidal ligands: a comparative molecular field analysis.
Menezes IR; Leitão A; Montanari CA
Steroids; 2006 Jun; 71(6):417-28. PubMed ID: 16481019
[TBL] [Abstract][Full Text] [Related]
10. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.
Kuiper GG; Lemmen JG; Carlsson B; Corton JC; Safe SH; van der Saag PT; van der Burg B; Gustafsson JA
Endocrinology; 1998 Oct; 139(10):4252-63. PubMed ID: 9751507
[TBL] [Abstract][Full Text] [Related]
11. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding.
Zhu BT; Han GZ; Shim JY; Wen Y; Jiang XR
Endocrinology; 2006 Sep; 147(9):4132-50. PubMed ID: 16728493
[TBL] [Abstract][Full Text] [Related]
12. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
[TBL] [Abstract][Full Text] [Related]
13. Identification of the structural requirements of the receptor-binding affinity of diphenolic azoles to estrogen receptors alpha and beta by three-dimensional quantitative structure-activity relationship and structure-activity relationship analysis.
Demyttenaere-Kovatcheva A; Cronin MT; Benfenati E; Roncaglioni A; Lopiparo E
J Med Chem; 2005 Dec; 48(24):7628-36. PubMed ID: 16302803
[TBL] [Abstract][Full Text] [Related]
14. Molecular structural characteristics as determinants of estrogen receptor selectivity.
Agatonovic-Kustrin S; Turner JV; Glass BD
J Pharm Biomed Anal; 2008 Sep; 48(2):369-75. PubMed ID: 18511229
[TBL] [Abstract][Full Text] [Related]
15. CoMSIA and docking study of rhenium based estrogen receptor ligand analogs.
Wolohan P; Reichert DE
Steroids; 2007 Mar; 72(3):247-60. PubMed ID: 17280694
[TBL] [Abstract][Full Text] [Related]
16. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
van Lipzig MM; ter Laak AM; Jongejan A; Vermeulen NP; Wamelink M; Geerke D; Meerman JH
J Med Chem; 2004 Feb; 47(4):1018-30. PubMed ID: 14761204
[TBL] [Abstract][Full Text] [Related]
17. Molecular mapping of heterocyclic diazene derivatives for estrogen receptor modulation.
Islam MA; Mukherjee A; Saha A
Indian J Biochem Biophys; 2012 Aug; 49(4):236-45. PubMed ID: 23077784
[TBL] [Abstract][Full Text] [Related]
18. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies.
Salum Lde B; Polikarpov I; Andricopulo AD
J Mol Graph Model; 2007 Sep; 26(2):434-42. PubMed ID: 17349808
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
Opera TI; Waller CL; Marshall GR
Drug Des Discov; 1994 Jul; 12(1):29-51. PubMed ID: 7578806
[TBL] [Abstract][Full Text] [Related]
20. Comparative molecular field analysis (CoMFA) model using a large diverse set of natural, synthetic and environmental chemicals for binding to the androgen receptor.
Hong H; Fang H; Xie Q; Perkins R; Sheehan DM; Tong W
SAR QSAR Environ Res; 2003; 14(5-6):373-88. PubMed ID: 14758981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
